| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| V A Curtis, P Wright, A Reveley, R Kerwin, J V Luce. Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. The British journal of psychiatry : the journal of mental science. vol 166. issue 5. 1995-08-31. PMID:7620750. |
effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. |
1995-08-31 |
2023-08-12 |
Not clear |
| W G Honer, G W MacEwan, L Kopala, S Altman, S Chisholm-Hay, K Singh, G N Smith, T Ehmann, S Ganesan, M Lan. A clinical study of clozapine treatment and predictors of response in a Canadian sample. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 40. issue 4. 1995-08-31. PMID:7621391. |
to study the clinical response to clozapine in patients with refractory schizophrenia. |
1995-08-31 |
2023-08-12 |
Not clear |
| H He, J S Richardso. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. International clinical psychopharmacology. vol 10. issue 1. 1995-08-30. PMID:7542676. |
although risperidone is effective in acute schizophrenia and in non-treatment-resistant schizophrenics, studies adequately comparing risperidone with clozapine in treatment-resistant schizophrenic patients remain to be published. |
1995-08-30 |
2023-08-12 |
human |
| L K Oyewumi, D J Freeman, D Vollic. Can low-dose clozapine pharmacokinetics predict steady-state plasma concentration? Therapeutic drug monitoring. vol 17. issue 2. 1995-08-25. PMID:7624901. |
low-dose clozapine (25-75 mg every 12 h) was administered to 21 treatment-resistant patients with schizophrenia who had been split into three groups. |
1995-08-25 |
2023-08-12 |
Not clear |
| L K Oyewumi, D J Freeman, D Vollic. Can low-dose clozapine pharmacokinetics predict steady-state plasma concentration? Therapeutic drug monitoring. vol 17. issue 2. 1995-08-25. PMID:7624901. |
these results suggest that individualized doses of clozapine for treatment-resistant patients with schizophrenia can be conveniently predicted from trough drug levels at the start of therapy. |
1995-08-25 |
2023-08-12 |
Not clear |
| M Weber, H Gerbe. [A high serum creatine kinase picture due to too much or too little exercise]. Deutsche medizinische Wochenschrift (1946). vol 120. issue 25-26. 1995-08-09. PMID:7600928. |
case 2 concerned a 28-year-old woman with paranoid schizophrenia who had taken several tablets of clozapine and then remained in bed for 3 days. |
1995-08-09 |
2023-08-12 |
Not clear |
| C J Schmidt, S M Sorensen, J H Kehne, A A Carr, M G Palfreyma. The role of 5-HT2A receptors in antipsychotic activity. Life sciences. vol 56. issue 25. 1995-07-24. PMID:7791509. |
in particular, the high affinity of clozapine for the 5ht2a receptor subtype has been suggested to contribute to its reduced side-effect liability, greater efficacy and its activity in therapy-resistant schizophrenia. |
1995-07-24 |
2023-08-12 |
Not clear |
| A Klimke, E Kliese. [The atypical neuroleptic clozapine (Leponex)--current knowledge and recent clinical aspects]. Fortschritte der Neurologie-Psychiatrie. vol 63. issue 5. 1995-07-20. PMID:7782019. |
for the use of clozapine in europe, it should be underlined that in 1992 the indication was restricted to "acute and chronic forms of schizophrenia" whereas formerly it was permitted to treat several other neuroleptic resistant syndromes with clozapine, e.g. |
1995-07-20 |
2023-08-12 |
Not clear |
| H Y Meltzer, J Kennedy, J Dai, M Parsa, D Rile. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 12. issue 1. 1995-07-05. PMID:7766285. |
the psychotic symptoms of the three patients studied responded to low doses of clozapine with plasma levels of clozapine between 4.5 and 16.1 ng/ml and n-desmethylclozapine between 2.6 and 6.1 ng/ml, much below the plasma clozapine levels usually found in clozapine-treated refractory schizophrenia or affective disorders (range 100 to 687 ng/ml). |
1995-07-05 |
2023-08-12 |
Not clear |
| M Laune. Clozapine in schizophrenia. Lancet (London, England). vol 345. issue 8962. 1995-06-29. PMID:7605499. |
clozapine in schizophrenia. |
1995-06-29 |
2023-08-12 |
Not clear |
| W T Carpenter, R R Conley, R W Buchanan, A Breier, C A Tamming. Patient response and resource management: another view of clozapine treatment of schizophrenia. The American journal of psychiatry. vol 152. issue 6. 1995-06-21. PMID:7755110. |
patient response and resource management: another view of clozapine treatment of schizophrenia. |
1995-06-21 |
2023-08-12 |
Not clear |
| J B Sebens, T Koch, G J Ter Horst, J Kor. Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. European journal of pharmacology. vol 273. issue 1-2. 1995-06-05. PMID:7737311. |
the persisting effect of clozapine in the nucleus accumbens may be of significance to the efficacy of this drug in treatment-refractory schizophrenia. |
1995-06-05 |
2023-08-12 |
rat |
| E Klieser, E Lehmann, E Kinzler, C Wurthmann, K Heinric. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. Journal of clinical psychopharmacology. vol 15. issue 1 Suppl 1. 1995-05-31. PMID:7537287. |
randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. |
1995-05-31 |
2023-08-12 |
Not clear |
| E Klieser, E Lehmann, E Kinzler, C Wurthmann, K Heinric. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. Journal of clinical psychopharmacology. vol 15. issue 1 Suppl 1. 1995-05-31. PMID:7537287. |
this study compares the antipsychotic efficacy and the tolerability of risperidone and clozapine in patients with schizophrenia. |
1995-05-31 |
2023-08-12 |
Not clear |
| E Klieser, E Lehmann, E Kinzler, C Wurthmann, K Heinric. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. Journal of clinical psychopharmacology. vol 15. issue 1 Suppl 1. 1995-05-31. PMID:7537287. |
the results suggest that risperidone is at least as effective as an antipsychotic as clozapine, providing a valuable new approach for the treatment of schizophrenia. |
1995-05-31 |
2023-08-12 |
Not clear |
| M Huttune. The evolution of the serotonin-dopamine antagonist concept. Journal of clinical psychopharmacology. vol 15. issue 1 Suppl 1. 1995-05-31. PMID:7730499. |
suggestions that serotonin might be involved in the cause of schizophrenia or could be a target for antipsychotic drug action began with the discovery that the antipsychotic agent clozapine is a potent serotonin 5-ht2a antagonist, as well as being a dopamine d2 antagonist. |
1995-05-31 |
2023-08-12 |
Not clear |
| R W Kerwi. Clozapine: back to the future for schizophrenia research. Lancet (London, England). vol 345. issue 8957. 1995-05-16. PMID:7715333. |
clozapine: back to the future for schizophrenia research. |
1995-05-16 |
2023-08-12 |
Not clear |
| S Szymanski, J Lieberman, S Pollack, A Safferman, R Munne, D Umbricht, J Kane, M Kronig, M Chakos, T Coope. Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: preliminary findings. Biological psychiatry. vol 37. issue 1. 1995-04-25. PMID:7893860. |
clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: preliminary findings. |
1995-04-25 |
2023-08-12 |
Not clear |
| C Bryoi. [New psychopharmacologic alternatives in treatment of schizophrenia]. Schweizer Archiv fur Neurologie und Psychiatrie (Zurich, Switzerland : 1985). vol 145. issue 6. 1995-04-12. PMID:7533941. |
clozapine, risperidone and remoxipride are three neuroleptics that represent an interesting alternative in the psychopharmacological treatment of schizophrenia. |
1995-04-12 |
2023-08-12 |
Not clear |
| I Jalenques, A J Couder. [Clozapine and refractory schizophrenia. Long-term prospective study of 20 patients]. L'Encephale. vol 20. issue 6. 1995-04-04. PMID:7875111. |
[clozapine and refractory schizophrenia. |
1995-04-04 |
2023-08-12 |
Not clear |